Evidence map›Paper›PMID 39740892›Full record

ArticleIn vivo (Athens, Greece)

Preclinical Assessment of Safety and Efficacy of Deferoxamine (DFO)-pretreated Feline Adipose Mesenchymal Stem Cells.

Hailong Teng, Minkyung Cho, Zhiqiang Ma, Xinpeng Ji, Shiyu Jin, Yuze Zhou, Meifu Xuan, Hyun-A Seong, Xiangzi Li, Seong-Ho Choi and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Hailong Teng *Department of Veterinary Medicine, Yanbian University, Yanji, P.R. China.
Minkyung Cho *Department of Biological Sciences and Biotechnology, Chungbuk National University College of Natural Science, Cheongju, Republic of Korea.
Zhiqiang MaYanji Livestock Station, Yanji, P.R. China.
Xinpeng JiDepartment of Veterinary Medicine, Yanbian University, Yanji, P.R. China.
Shiyu JinDepartment of Veterinary Medicine, Yanbian University, Yanji, P.R. China.
Yuze ZhouDepartment of Veterinary Medicine, Yanbian University, Yanji, P.R. China.
Meifu XuanEngineering Research Center of North-East Cold Region Beef Cattle Science & Technology Innovation, Ministry of Education, Yanbian University, Yanji, P.R. China.
Hyun-A SeongDepartment of Biological Sciences and Biotechnology, Chungbuk National University College of Natural Science, Cheongju, Republic of Korea.
Xiangzi LiEngineering Research Center of North-East Cold Region Beef Cattle Science & Technology Innovation, Ministry of Education, Yanbian University, Yanji, P.R. China.
Seong-Ho Choi *Department of Biological Sciences and Biotechnology, Chungbuk National University College of Natural Science, Cheongju, Republic of Korea; seongho@cbnu.ac.kr.
Qiang Li *Department of Veterinary Medicine, Yanbian University, Yanji, P.R. China; liqiang8589@ybu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimThis study aimed to investigate the safety and efficacy of deferoxamine (DFO) pretreated feline adipose tissue derived mesenchymal stem cells (fATMSCs) for the treatment of inflammatory disorders. MATERIALS AND

methodsfATMSCs were isolated from feline adipose tissue and characterized using flow cytometry for surface marker expression and differentiation assays for adipogenic, osteogenic, and chondrogenic lineages. Different concentrations of DFO were used to evaluate its impact on fATMSC activity. The therapeutic potential of these preconditioned cells was validated using a mouse model of acute lung injury (ALI) by LPS injection. Comprehensive evaluations, including clinical, hematological, and radiological assessments, were conducted before and after intravenous injection of preconditioned cells in three feline subjects.

results25 μM DFO pretreatment significantly up-regulated immunomodulatory genes (Tgfb, Hgf, and Tsg-6) in fATMSCs. In the mouse ALI model, DFO-pretreated fATMSCs exhibited enhanced anti-inflammatory effects, reducing inflammatory cytokines (Tnfa, Il1b, Il6). Clinical safety assessment in felines showed no immediate adverse effects, structural alterations, or tumorigenesis.

conclusionUtilizing a mouse model of acute lung injury, we demonstrated the potential of DFO-pretreated fATMSCs as a safe and effective therapeutic approach for inflammatory disorders.

Indexed as

Acute Lung InjuryAdipose TissueCell DifferentiationDeferoxamineDisease Models, AnimalMesenchymal Stem CellsMesenchymal Stem Cell TransplantationAnimalsBiomarkersCatsCells, CulturedCytokinesMiceBiomarkersCytokinesDeferoxamineacute lung injuryDeferoxamineinflammatory disordersmesenchymal stem cellsmouse model

Identifiers

PMID39740892
PMCPMC11705137

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.